EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Standard-Dose Versus Low-Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma—A Retrospective Analysis

Chirag Trivedi iD, Junita John, Sujith Karumathil iD, Sushil Selvarajan iD, Sharon Lionel iD, Julie Hephzibah, Saumya Sunny, Anuradha Chandramohan, Uday Kulkarni iD, Kavitha Lakshmi iD, Fouzia Nambiatheyil Aboobacker, Aby Abraham iD und 3 weitere

JCO Global Oncology · 2026-02 · 12 (2)

DOI: 10.1200/go-25-00424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2026-02. Verfasst von Chirag Trivedi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Christian Medical College, Vellore, India. Hauptthemen laut MEDLINE: Nivolumab, Hodgkin Disease, Antineoplastic Agents, Immunological, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE As there is a paucity of data comparing outcomes with different dosing regimens of PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma (R/R HL), this retrospective analysis was undertaken to compare the efficacy of low-dose nivolumab (fixed at 40 mg) with the standard dose of 3 mg/kg. METHODS Single-center retrospective analysis of patients with R/R HL who failed at least one salvage regimen and were treated with nivolumab between 2015 and 2023, at either 3 mg/kg (standard-dose nivolumab [SD-NIV]) or a flat dose of 40 mg (NIV40), both administered once in 2 weeks. Treatment response was assessed with 18 F-labeled fluorodeoxyglucose-positron emission tomography-computed tomography after four doses of nivolumab. RESULTS A total of 45 patients were included: 25 received 3 mg/kg (SD-NIV) and 20 received a flat dose of 40 mg (NIV40). The mean dose of nivolumab administered once in 2 weeks was 2.9 mg/kg (stable disease 0.31) in the SD-NIV group compared with 0.6 mg/kg (stable disease 0.10) in the NIV40 group ( P < .001). Responses after four doses of nivolumab were similar in the SD-NIV versus NIV40 group: complete response (48% v 50%), partial response (12% v 10%), stable disease (20% v 20%), and progressive disease (20% v 20%; P = .997). Immune-related adverse effects were similar in the two groups (12% v 10%; P = .790). Two-year event-free survival (EFS) of the whole cohort treated with nivolumab with SD-NIV and NIV40 was 47% and 49.5%, respectively ( P = .788). Twenty-two of the 45 patients underwent stem cell transplant (11 from each group), with a 2-year EFS of 90.1% versus 81.8% ( P = .545) in the SD-NIV and NIV40 groups, respectively. CONCLUSION Despite the inherent limitations of a retrospective analysis, the data suggests that nivolumab demonstrates biologic efficacy at doses as low as 0.6 mg/kg. Prospective trials comparing different dosing strategies are clearly warranted; such studies may facilitate approval of biologically active and cost-effective regimens, thereby broadening access to checkpoint inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabHodgkin DiseaseAntineoplastic Agents, ImmunologicalNeoplasm Recurrence, LocalHumansRetrospective StudiesFemaleMaleAdultMiddle AgedTreatment Outcome

Substanzen

NivolumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Haematology, Christian Medical College, Vellore, India.
  • Department of Nuclear Medicine, Christian Medical College, Vellore, India.
  • Department of Radiodiagnosis, Christian Medical College, Vellore, India.

ORCID-Profile: Chirag Trivedi, Sujith Karumathil, Sushil Selvarajan, Sharon Lionel, Uday Kulkarni, Kavitha Lakshmi, Aby Abraham, Biju George, Vikram Mathews, Anu Korula

Zitieren

APA

Trivedi, C., John, J., Karumathil, S., Selvarajan, S., Lionel, S., Hephzibah, J., Sunny, S., Chandramohan, A., Kulkarni, U., Lakshmi, K., Nambiatheyil Aboobacker, F., Abraham, A., George, B., Mathews, V., & Korula, A. (2026). Efficacy of Standard-Dose Versus Low-Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma—A Retrospective Analysis. JCO Global Oncology, 12(2). https://doi.org/10.1200/go-25-00424

Vancouver

Trivedi C, John J, Karumathil S, Selvarajan S, Lionel S, Hephzibah J, et al. Efficacy of Standard-Dose Versus Low-Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma—A Retrospective Analysis. JCO Global Oncology. 2026;12(2). doi:10.1200/go-25-00424

BibTeX
@article{Trivedi2026,
  author = {Trivedi, Chirag and John, Junita and Karumathil, Sujith and Selvarajan, Sushil and Lionel, Sharon and Hephzibah, Julie and Sunny, Saumya and Chandramohan, Anuradha and Kulkarni, Uday and Lakshmi, Kavitha and Nambiatheyil Aboobacker, Fouzia and Abraham, Aby and George, Biju and Mathews, Vikram and Korula, Anu},
  title = {Efficacy of Standard-Dose Versus Low-Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma—A Retrospective Analysis},
  journal = {JCO Global Oncology},
  year = {2026},
  volume = {12},
  number = {2},
  doi = {10.1200/go-25-00424}
}
Kostenlos starten →